skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Executive Summary



A lawsuit claims that Trump overstepped presidential authority.

 


A lawsuit has been filed arguing President Trump's "one in, two out" executive order to reduce government regulation is unconstitutional.


Public Citizen, along with the National Resources Defense Council and Communications Workers of America, filed suit Feb. 8 in US District Court for the District of Columbia arguing that the executive order exceeds presidential authority and "directs federal agencies to engage in unlawful actions that will harm countless Americans."


The groups want the court to rule the executive order cannot be implemented lawfully and prevent it from taking effect. A White House response is expected within 60 days, but no hearing has been set.


Trump issued the executive order Jan. 30, requiring that the cost of a new regulation be offset by elimination of two existing regulations. It is a concern for some in part because it could increase uncertainty and limit FDA's ability to provide industry with a framework on various subjects, but it also presents some opportunities for industry, stakeholders say. (Also see "Trump's Two-For-One Reg Order Needs Agency Interpretation, Medtech Reg Experts Say" - Medtech Insight, 30 Jan, 2017.)


The Office of Management and Budget issued clarifying guidance on the order Feb. 2 that appears to limit its application as it relates to FDA, however. (Also see "US FDA Could Be Mostly Spared From Trump's Regulation-Slashing Order" - Medtech Insight, 13 Feb, 2017.)


The suit states that federal agencies complying with the executive order would violate their governing statutes. In addition, it argues the executive order usurps congressional legislative authority and violates the presidential obligation to "take care that the law shall be faithfully executed."

 

Public Citizen's complaint does not mention FDA specifically, instead focusing on concerns about the order's effect on laws governing motor vehicle safety, clear air, occupational health and safety, and other areas.


"The public interest favors entry of a declaration that the executive order is contrary to law and unconstitutional because implementation of the executive order will deter, weaken, delay, and eliminate regulations that protect plaintiffs and the public from harm," the groups wrote in the suit.


White House spokesman Sean Spicer said during a Feb. 8 press briefing that the suit "is wildly inaccurate" and that everybody should welcome a review of regulations to make sure they are not stifling job creation. "[The suit] makes a ton of assumptions that call for speculation on what may or may not happen in the future," he said. "It's just subjective at best."

 

Find more content on the US election here.

Read also

  • Biomedtracker: follow the drug development process

    Biomedtracker 2018 Early Outlook Report

    What's on the horizon for pharma in 2018? Find out with Biomedtracker&rsquo;s Early 2018 Outlook Report extract. Download free extracts from this essential report, which investigates the catalysts expected to occur in the first part of the year for 21 different drugs.<br />

    Topics Drug development landscape

  • Biomedtracker: follow the drug development process

    Accurate, Intuitive and Updated In Real Time

    03 Apr 2017

    Learn why pharmaceutical, biotech, and investment companies rely on BioMedTracker for its insight on the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication.

  • Scrip: industry news and insights

    Hong Kong Takes On Nasdaq For China Biotech IPOs

    By Brian Yang

    <span style="color: #58595b; text-align: start; letter-spacing: normal;">Hong Kong is catching global attention as it plans to drastically change listing rules for biotech firms, potentially opening the way to both Chinese companies seeking public funding and international firms eyeing entry to China. A Shanghai biosimilars developer, among others, is now eyeing an offering.</span>

    Topics Policy and regulation

;

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: